Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6120240 | 0.84 | TSHR (0.36) | TSHR | |
| SCHEMBL646025 | 0.75 | CA14 (0.38) | CA14CA12CA2CA1DGAT1 | |
| SCHEMBL20262979 | 0.74 | CA14 (0.42) | CA14CA12CA2CA1DGAT1 | |
| SCHEMBL7023795 | 0.73 | CA14 (0.39) | CA14CA12CA2CA1DGAT1 | |
| SCHEMBL1688828 | 0.72 | CA14 (0.41) | CA14CA12CA2CA1DGAT1 | |
| SCHEMBL16400136 | 0.71 | DGAT1 (0.34) | DGAT1HDAC1HDAC2HDAC6 | |
| SCHEMBL15253867 | 0.70 | CA14 (0.40) | CA14CA12CA2CA1DGAT1 | |
| SCHEMBL883067 | 0.70 | CA2 (0.39) | CA14CA12CA2CA1DGAT1 | |
| SCHEMBL4805641 | 0.69 | ABCB1 (0.47) | — | |
| SCHEMBL2528429 | 0.69 | KDM1A (0.42) | HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023747-A1 | Cysteine Protease Inhibitors | MEDIVIR AB (SE) | 2009-01-22 | — | — | US | disclosed |
| EP-1899336-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007006714-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007006716-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006064286-A1 | CATHEPSIN S INHIBITORS | MEDIVIR UK LTD (GB) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023747-A1 | Cysteine Protease Inhibitors | CTSK, CTSS, CTSZ | CA14 356/4885CA12 518/4885CA2 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.